Strategic Partnerships Leverage Adial's recent Azora Therapeutics acquisition and board expansions to explore co-development, licensing, or strategic investment conversations with firms in biotech and specialty pharma seeking additive assets in addiction, neurology, or GI spaces.

Clinical Progress Target discussions with CROs, trial services, and companion diagnostic developers around the AD04 program and the ONWARD Phase 3 trial to offer study design support, patient recruitment optimization, and data analytics collaboration.

Genetic Diagnostics Position companion diagnostic capabilities as a gateway for pharma partners focusing on precision medicine in AUD and related addictions, offering collaborative development and commercialization plans.

Expanded Portfolio Explore opportunities with pain and other disorders through adenosine analogs pipeline and the AhR-based AT177 program post-acquisition to identify co-development or out-licensing candidates.

Strategic Financing Capitalize on recent leadership hires and stock-based incentives to engage potential investors and strategic buyers by highlighting growth vector, upcoming milestones, and potential up-round financing needs.